EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the most widely used targeted therapies and are remommended as first-line treatment for NSCLC patients with EGFR activating mutations (National Comprenhensive Cancer Network, 2017; He et al., 2021). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.